These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 12397699

  • 21. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
    Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
    Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M.
    Nefrologia; 2009 Oct 26; 29(5):421-9. PubMed ID: 19820754
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
    Transplant Proc; 2005 Mar 26; 37(2):991-3. PubMed ID: 15848600
    [Abstract] [Full Text] [Related]

  • 26. Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
    Robles NR, Fernandez Carbonero E, Romero B, Sánchez Casado E, Cubero JJ.
    Cardiovasc Ther; 2009 Mar 26; 27(2):101-7. PubMed ID: 19426247
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
    Sebeková K, Lill M, Boor P, Heidland A, Amann K.
    Am J Nephrol; 2009 Mar 26; 29(3):164-70. PubMed ID: 18753741
    [Abstract] [Full Text] [Related]

  • 30. Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan.
    Tomiyama H, Motobe K, Zaydun G, Koji Y, Yambe M, Arai T, Kushiro T, Yamashina A.
    Am J Hypertens; 2005 Feb 26; 18(2 Pt 1):178-82. PubMed ID: 15752944
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Successful treatment of combination therapy using an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker in a patient with IgA nephropathy].
    Horino T, Ito H, Tanimoto N, Yoshida T, Sasaoka A, Chijiwa T, Hosokawa T, Hashimoto K.
    Nihon Jinzo Gakkai Shi; 2003 Feb 26; 45(2):104-8. PubMed ID: 12703406
    [Abstract] [Full Text] [Related]

  • 33. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
    Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, Karashima S, Yamagishi M.
    Am J Hypertens; 2007 Dec 26; 20(12):1329-33. PubMed ID: 18047925
    [Abstract] [Full Text] [Related]

  • 34. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 26; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 35. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R.
    J Card Fail; 2007 Mar 26; 13(2):86-94. PubMed ID: 17395047
    [Abstract] [Full Text] [Related]

  • 36. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H.
    Transplantation; 2003 Oct 27; 76(8):1170-4. PubMed ID: 14578748
    [Abstract] [Full Text] [Related]

  • 37. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
    Fogari R, Zoppi A, Mugellini A, Maffioli P, Lazzari P, Derosa G.
    Hypertens Res; 2011 Dec 27; 34(12):1321-6. PubMed ID: 21814211
    [Abstract] [Full Text] [Related]

  • 38. Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
    Ohtake T, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Kobayashi S.
    Hypertens Res; 2008 Mar 27; 31(3):387-94. PubMed ID: 18497456
    [Abstract] [Full Text] [Related]

  • 39. [Clinical effects of trandolapril in chronic glomerulonephritis patients with renal insufficiency].
    Yoshida A, Takeda A, Fukuda M, Toda S, Morozumi K.
    Nihon Jinzo Gakkai Shi; 2000 May 27; 42(4):333-7. PubMed ID: 10897592
    [Abstract] [Full Text] [Related]

  • 40. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
    Kurokawa K, Abe K, Saruta T, Arakawa M, Kikkawa R, Ueda N, Onoyama K, Tomita K, Ogawa N.
    J Renin Angiotensin Aldosterone Syst; 2002 Sep 27; 3(3):167-75. PubMed ID: 12563567
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.